|  |  |  |  |
| --- | --- | --- | --- |
| Timepoint post HSCT (auto and allo) | Pathogens Protected Against | Vaccine  | Trade Name (Equivalent alternative may be used) |
| SARS-CoV-2 re-vaccination Age 5-11 |
| 3-6 months  | SARS-CoV-2 | Pfizer-BioNTech mRNA BNT162b2 (Dose 1) [[1]](#endnote-1) | As per vaccine name |
| Minimum 12 weeks post-dose 1 | SARS-CoV-2 | Pfizer-BioNTech mRNA BNT162b2 (Dose 2) 1 | As per vaccine name |
| SARS-CoV-2 re-vaccination Age 12-17 |
| 3-6 months | SARS-CoV-2 | Pfizer-BioNTech mRNA BNT162b2 (Dose 1) *OR*Moderna mRNA 1273 (Dose 1*OR*Novavax NVX-CoV2373 (Dose 1)2 | As per vaccine name |
| Minimum 8 weeks post-dose 1 | SARS-CoV-2 | Pfizer-BioNTech mRNA BNT162b2 (Dose 2) *OR*Moderna mRNA 1273 (Dose 2)*OR*Novavax NVX-CoV2373 (Dose 1)2 | As per vaccine name |
| 8 weeks post dose 2 | SARS-CoV-2 | Pfizer-BioNTech mRNA BNT162b2 (Dose 3) *OR*Moderna mRNA 1273 (Dose 3)*OR*Novavax NVX-CoV2373 (Dose 1)2 | As per vaccine name |
| Routine re-vaccination Age <18 |
| Annually from 6 months (Consider from 3 months) | Seasonal Influenza | Seasonal inactivated Influenza vaccine | As per vaccine name |
| 6 months | Diphtheria, tetanus, pertussis, polio, *Haemophilus influenzae* b, Hepatitis BMeningococcal B*Streptococcus* *pneumoniae*Human Papillomavirus3 | DTaP/IPV/Hib/HepB (dose 1)Men B (dose 1)PCV13 (dose 1)Quadrivalent HPV (dose 1) | Infanrix hexa or VaxelisBexseroPrevenar 13Gardasil |
| 7 months | Diphtheria, tetanus, pertussis, polio, *Haemophilus influenzae* b, Hepatitis B*Streptococcus* *pneumoniae*Human Papillomavirus3 | DTaP/IPV/Hib/HepB (dose 2)PCV13 (dose 2)Quadrivalent HPV (dose 2) | Infanrix hexa or VaxelisPrevenar 13Gardasil  |
| 8 months | Diphtheria, tetanus, pertussis, polio, *Haemophilus influenzae* b, Hepatitis BMeningococcal BMeningococcal ACWY*Streptococcus* *pneumoniae* | DTaP/IPV/Hib/HepB (dose 3)MenB (dose 2)Men ACWY (dose 1)PCV13 (dose 3) | Infanrix hexa or VaxelisBexseroNimenrix or MenveoPrevenar 13 |
| 12 months | Human Papillomavirus3 | Quadrivalent HPV (dose 3) | Gardasil |
| 18 months | Meningococcal ACWYMeningococcal B*Streptococcus* *pneumonia*e | Men ACWY (dose 2)Men B (Booster)PPSV23 Or PCV134 (Booster) | Nimenrix or MenveoBexseroPneumovaxPrevenar 13 |
| 24 months | Measles, Mumps, Rubella5VaricellaHuman Papillomavirus3 | MMR (dose 1) *live vaccine*Varicella vaccine (dose 1) *live vaccine*Quadrivalent HPV (dose 3) | MMR VaxPro or PriorixVarivax or VarilrixGardasil |
| 26 months | Varicella | Varicella vaccine (dose 2) *live vaccine* | Varivax or Varilrix |
| 30 months | Measles, Mumps, Rubella5 | MMR (dose 2) *live vaccine* | MMR VaxPro or Priorix |
| 3 years | Diphtheria, tetanus, pertussis and polio | DTaP/IPV (Booster 1) | Repevax or Boostrix IPV |
| 14 years | Diphtheria tetanus, polio | Td/IPV (Booster 2) | Revaxis |

1. The paediatric formulation (10 micrograms) of the Pfizer-BioNTech mRNA vaccine should be administered to patients aged 5-11

2Novavax NVX-CoV2373 to be used only if mRNA vaccine use in clinically contraindicated

3HPV vaccine should be offered to all children aged 12 or over

4PPSV23 if no GvHD or Immunosuppresive therapy (IST), PCV13 if GvHD or IST

5Criteria for administration of live vaccines.  i) 24 months post HSCT ii) No GvHD iii) No IST for 12 months  iv) In remission v) No IVIg in last 3 months. Nb measles serology not mandated in paediatric population [↑](#endnote-ref-1)